Zimmer Biomet Holdings Inc.

ticker: ZBH step: 01 generated: 2026-05-13 source: quick-research

Zimmer Biomet Holdings, Inc. (ZBH) — Business Overview

Business Description

Zimmer Biomet (NYSE: ZBH) is a global medical technology company and one of the world's largest manufacturers of orthopedic reconstructive implants, with leading positions in knee replacements, hip replacements, and shoulder arthroplasty. The company designs, manufactures, and sells joint replacement systems, surgical instruments, and related digital/robotic surgery platforms to hospitals and ambulatory surgery centers (ASCs) worldwide. The 2022 spin-off of ZimVie (spine and dental) refocused Zimmer Biomet on its core reconstructive joint business. The company operates across approximately 40 countries with manufacturing facilities in the U.S., Europe, and Asia-Pacific.

Revenue Model

Revenue is generated from the sale of orthopedic implants and instruments — predominantly through a direct hospital/ASC sales force of field reps who maintain surgeon relationships and facilitate surgical procedures. The business is non-recurring at the transaction level (each implant sale is a one-time event) but highly predictable at the population level — driven by demographic aging, obesity rates, and activity levels. Pricing is set through hospital group purchasing organizations (GPOs), integrated delivery networks (IDNs), and direct surgeon/hospital negotiations, with ~1% annual pricing erosion typical in the industry.

Products & Services

• Persona IQ "The Smart Knee": World's first smart knee implant with embedded sensors capturing gait and ROM data post-operatively
• ROSA Knee System: Robotic-assisted total knee arthroplasty — flagship robotic platform; with OptimiZe AI planning
• ROSA Hip System: Robotic-assisted total hip arthroplasty
• ROSA Shoulder (2024): World's first robotic system for shoulder replacement; performed nation's first outpatient robotic shoulder replacement in ASC (April 2026)
• TMINI Miniature Robotic System: Compact surgical robotics for total knee
• Monogram Technologies TKA: Semi-/fully-autonomous robotic technology (acquisition completed)
• OrthoGrid Hip AI: AI surgical guidance for hip procedures (acquired 2024)
• Z1 Triple-Taper Femoral Hip: New cementless hip system (2025)
• Oxford Cementless Partial Knee: Unicompartmental knee replacement

Customer Base & Go-to-Market

Hospital systems, academic medical centers, and ASCs are the primary customers, with orthopedic surgeons as the key decision-makers/influencers. Large hospital systems purchase through GPO contracts; individual surgeons often drive implant selection based on training and preference, creating sticky relationships. The shift of joint replacement procedures to ASCs (lower cost, better patient convenience) is a key trend affecting the channel mix.

Competitive Position

Zimmer Biomet is the #2–#3 global orthopedic company behind Stryker and DePuy Synthes (J&J). Stryker's Mako robotic system has materially outperformed ROSA in U.S. robotic adoption, creating a competitive disadvantage in the fastest-growing segment of the orthopedic market. However, ZBH's "Magnificent Seven" technology portfolio — ROSA Knee, ROSA Shoulder, ROSA Hip, Persona IQ, OrthoGrid, Monogram, Oxford Cementless — is designed to close the gap. ZBH retains strong surgeon relationships built over decades and a comprehensive implant catalog across all major joints.

Key Facts

• Founded: 1927 (as Zimmer Manufacturing Company)
• Headquarters: Warsaw, Indiana
• Employees: ~18,000
• Exchange: NYSE
• Sector / Industry: Health Care / Health Care Equipment & Supplies
• Market Cap: ~$9B

ticker: ZBH step: 04 generated: 2026-05-13 source: quick-research

Zimmer Biomet Holdings, Inc. (ZBH) — Financial Snapshot

Income Statement Summary

FY2022 GAAP earnings depressed by ZimVie spin-off charges and restructuring costs. FY2023–FY2024 reflect the cleaner post-spin business. Adjusted (non-GAAP) EPS substantially higher — adjusted EPS FY2024 ~$8.00+ range, excluding amortization of acquired intangibles (large balance from the 2015 Biomet merger).

Cash Flow & Balance Sheet (FY2024)

High debt load reflects legacy financing from the 2015 Zimmer-Biomet merger ($13.35B deal). Leverage has declined but remains elevated. The 2024 Paragon 28 acquisition (foot/ankle orthopedics) added incremental debt and near-term margin dilution.

Key Ratios (approximate)

• P/E: ~15x (adjusted) | EV/EBITDA: ~9x | FCF Yield: ~9%
• Revenue Growth (FY2024): +3.8% (+4.8% constant currency)
• Revenue Growth (FY2023): +6.5% (+7.5% constant currency)
• Adjusted EPS growth has been inconsistent due to acquisition activity and restructuring

Growth Profile

Zimmer Biomet's revenue growth has been in the low-to-mid single digit range, below orthopedic market growth rates (5–6%/year), reflecting market share losses — particularly in robotics where Stryker's Mako system has dominated. The ZimVie spin-off (2022) removed ~$1B in revenue and clarified the ZBH equity story. FY2024 growth of ~4.8% constant currency is modestly below market, reflecting continued robotics competitive pressure and international market challenges. The Paragon 28 acquisition (foot/ankle, closed 2024) adds ~$250–300M in annual revenue at a segment still investing for growth.

Forward Estimates

• Q3 FY2025 Net Sales: $2.001B (reported — continuing ~3% growth pace)
• FY2026 Operating Margin Guidance: ~50bp decrease vs. FY2025 (lower gross margins, Paragon 28 dilution, increased R&D)
• FY2026 Pricing Headwind: ~100bp erosion expected
• Analyst consensus: Mixed — William Blair Market Perform; price target range roughly $95–$172 reflecting execution uncertainty